

Supplementary material

Supplementary figure 1 A)

In silico characterization of *var* gene primers used in the present study

Supplementary figure 1 B)

In silico comparison of new DBL α targeting primers to old versions published by Lavstsen et al. PNAS, 2012

Supplementary Figure 2.

Overview of PfEMP1 domain classes, the estimated proportion of *var* genes encoding these, and predicted coverage of applied primer sets.

Supplementary Figure 3:

Transcript levels by primer sets reporting statistically significant different transcript levels between hospitalized patients with uncomplicated and severe malaria.





Supplementary Figure 4:

Median (25 and 75 percentiles, upper and lower adjacent values and outliers) *var* transcript levels (Tu) reported in children with severe malarial anaemia (N=44) or cerebral malaria (N=29) with the primer set targeting DBL1/3-1.






Supplementary Table 1.




Percentage of individuals of each patient group with *var* transcript levels higher than 16 Tu

Supplementary Figure 1A - In silico characterization of *var* gene primers used in the present study








Primer name (Target domain type)	Forward primers	Reverse primers	Amplicon size	Coverage	Specificity	
	Mixed to a final total primer concentration of 20 μ M	Mixed to a final total primer concentration of 20 μ M	Median (Min - Max) bp	Number of sequences amplified with intended domain class / number of sequences with intended domain class (%)	Number of sequences amplified with intended domain class / number of domain sequences amplified (%)	
CIDRa1.1 (CIDR α 1.1)	TGGGAACATCAACTTAAGGATTGATA TGGGAACATCAACTTAAGAATTGATA TGGGAACATGAACCTTAAGGATTGATA	TAAATCTTCNTAAATTGATHCCAT	270 (270-273)	274/290 (95%)	274/277 (99%)	
CIDRa1.8a (CIDR α 1.8a)	ATAATTGTGAAATGAAAGTTCA	TATGCAMTTCTTAAGTTGGTTCC	140 (140-140)	104/104 (100%)	104/104 (100%)	
CIDRa1.8b (CIDR α 1.8b)	AATAGACAGTATAATGTGGAA AAAGGATACTATAAGTGGAA	CAAAACATWTACAATTCGTTACA	101 (98-101)	61/61 (100%)	61/122 (50%) [Off target sequences also targeted by CIDRa1.4 and CIDRa1.6b primers, albeit all with 2 mismatches]	
CIDRa1.8 (CIDR α 1.8)	Comment: A summarized transcript level for CIDR α 1.8 domains (CIDR α 1.8a+8b). There is no overlap between targeted sequences.					
CIDRa1.DC8	Comment: A summarized transcript level for DC8 domains (CIDR α 1.1+CIDR α 1.8a+8b). There is no overlap between targeted sequences.					
CIDRa1.4/6a (CIDR α 1.4/6a)	AACTATCAAAATGGGAATGCTATTAA AACTATGACCAATGGAAATGCTATTAA AACTATCAAATGGAAATTGCTATTAA AACTATGAAAATGGCAATGCTATTAA AACAAATCAAATATGGAAATGCTATTAA	AATGGGGACAACAAAAACAAAAATATG	163 (163-172)	CIDR α 1.4: 281/345 (81%) CIDR α 1.6a: 31/54 (58%)	312/319 (98%)	
CIDRa1.5a (CIDR α 1.5a)	GATTATGGATTAAGAATTATTAAAG GATTGTGGTTACGAATTATTAAAG GATTGTGGTTACATATTATTAAAG	TAATTCTATCGTAAATTCTTCCA CAAATCTTCTTAAGTTTTTCCA TAATTCTATCGTAAATTGATTCCA CAAATCTTCTTAAGTTTTTCCA	306 (306-306)	98/104 (94%)	98/98 (100%)	
CIDRa1.5b (CIDR α 1.5b)	ACGATACATAGACTGGAAATACG ATTGGAAWATAAACCTTAAAGCTG TGGTACTACAGATTGGATCGTA	AACCCATTGTCAAAACATTACA AACCCATTATCAAAACAGTACA AACCCATTATCAAACACATACA	110 (98-113)	119/124 (96%)	114/114 (100%)	
CIDRa1.5	Comment: A summarized transcript level for CIDR α 1.5 (CIDR α 1.5a+CIDR α 1.5b). There is no overlap between targeted sequences.					
CIDRa1.6b (CIDR α 1.6b)	ATAACTAATGTSACGGATTG	CAGTTCTTATACATCCCATTC ACATCCTTATACACCCATTC AATTCTTATACCTCCATTCTG	107 (104-107)	81/81 (100%)	81/112 (72%) [50% of the targeted genes are also targeted by 3 other primer sets: CIDR α 1.4/7/8b]	

Primer name (Target domain type)	Forward primers	Reverse primers	Amplicon size	Coverage	Specificity
	Mixed to a final total primer concentration of 20 μ M	Mixed to a final total primer concentration of 20 μ M	Median (Min - Max) bp	Number of sequences amplified with intended domain class / number of sequences with intended domain class (%)	Number of sequences amplified with intended domain class / number of domain sequences amplified (%) Specificity graphic
CIDRa1.7 (CIDRa1.7)	CGGAAACTATAACGTGGAACGATAA CGGAAACTATAAGGTGAAACGATAA CGGAAACTATAACGTGGAAGATAA GGATACATAATGTGGATGATAAA	TAGTTTCTTATACATTCCATT TAGTTCTTATACATTCCATT TAGTTTCTTATATTATTCCATT TAGTTCTTATACATTCCATT TAATTCCATTATATTATTCCATT	148 (145-149)	277/282 (99%)	277/395 (70%) [unintended hits are all var1 CIDRa1.2]
CIDRa1.A (CIDRa1 of group A)	Comment: A summarized transcript level for all group A CIDRa1 domains (CIDRa1.4-7 primers). There is an estimated 2% of genes targeted twice by these primer sets.				
CIDRa1.all (All CIDRa1)	Comment: A summarized transcript level for all CIDRa1 domain primers. There is an estimated 5% of genes targeted twice by these primer sets.				
CIDRd (N-terminal CIDR δ)	TAAATGTAACCTAGATGTATGTGAAC TAAATGTAACCTACATGTATGTGAAC TAAATGTAACCTAGACGTATGTGAAC TAAATGTTACTTAGATGTATGTGAAC TAAATGTAACCTAGATATGTGAAC TAAATGTAAGTAGATGTATGTGAAC	AATACTTAAACCAACGTTAACATAC AATACTTAAACCAACGCTAACATAC AATACTGCAACCAACGTTAACATAC AATGCTTAACCAACGTTAACATAC AATAACATCACCAACGCTAACATAC	104 (104-104)	308/410 (75%)	308/350 (88%)
CIDRg3.1 (CIDR γ 3.1)	TATGTATATGCTGATGAACGTATTAC	TTCTATCCATTTCTAAACATTC	174 (174-174)	81/81 (100%)	81/81 (100%) [The N-terminal group A CIDR γ domains (ie. CIDR γ 3 domains) are diversified into several small subgroups of which the CIDR γ 3.1 is the largest (~20% of CIDR γ 3)]
CIDRa3.1/2 (CIDRa3.1/2)	AHWWVAAAAGACRTWCHATRATT AHWWVAAAAGACRTCAATCCT ARAAAGTAAAGGATTATGTWGRTTT	TTTTGTTCTCCAATRTATRGAATC	80 (80-81)	1479/1970 (75%) CIDRa2-6: 1536/9142 (17%)	1479/1536 (96%) CIDRa2-6: 1536/1536 (100%)
DBLa2/1.1/2/4/7 (DBLa2/1.1/2/4/7)	GATTAYGTBCCTCAATTTTAMGWTGGT	TACAATCATATCCATTAWGACTACAA TCACAATCGCATCCATTATGACTACAA	145 (145-157)	1422/1736 (82%)	1422/1489 (82%)
DBLa1.5/6/8 (DBLa1.5/6/8)	GATTAYGTBCCTCAATTTTAMGWTGGT	TTTTAGTACAATCATACCATCACCA GATTGGTTTWTACAATCGTAACCCCTC ACAATCCTCACCATCACCACTACAAT CGTGATATACTGTGTTAGTACAATC GATCTGTTGTTACAATCGTAACCCCTC	157 (144-173)	596/812 (73%)	596/666 (90%)
DBLa1all (DBLa1.1-8)	TTGGGAAATGTRTRGTTACAGCAA TTGGGAAATGTTAGTTATGCCAA TTGGGAAATTGTTAGTTATGCCAA TTGGGAAACCTATTGTTATGCCAA TTAGGAAATATTTGGTAGCAGCAA TTAGGAAATATCTTGGTCACAGCAA	CCTATATCNGCAAACTCKCKWGC	116 (116-128)	2211/2404 (92%)	2211/2211 (100%)
DBLb1/3-1 (Group A DBL β 1/3, subdomain 3)	TATACAAAASAGCAGAAATTATGC TAGCAGAAAAGCAGCAATTGTTGCTA	TTATAATACCCAGGACCRCATT	52 (50-52)	N/A (8% of DBL β 3) (25% of DBL β 1 not var1)	N/A


Primer name (Target domain type)	Forward primers	Reverse primers	Amplicon size	Coverage	Specificity
	Mixed to a final total primer concentration of 20 μ M	Mixed to a final total primer concentration of 20 μ M	Median (Min - Max) bp	Number of sequences amplified with intended domain class / number of sequences with intended domain class (%)	Number of sequences amplified with intended domain class / number of domain sequences amplified (%) Specificity graphic
DBLb1/3-2 (Group A DBL β 1/3, subdomain 3)	AACATGCACKAGTCGATATTGCT	CAGTAGAAGTWTARGACCACAT	51 (51-51)	N/A (5% of DBL β 3) (18% of DBL β 1 not var1)	N/A
DBLb5-S1 (DBL β 5 subdomain 1)	AACAAAGTAGGGTATCAAATGCAT ACAAACARYRGCACAMCWAATGCATVA	CCTTKTGTGCATYRSCCYTYAA	92 (89-95)	521/661 (79%) [No target overlap with other DBL β primers]	
DC5 (DBL β domains in DC5)	GTTGCTCCYMCCTTTGTAATGT CCCCCHCCYTCTTGTAAYGTNCC TTGCACCCATTTTGTAATATGCC	ACCACRTTGGTCGCATCTTGTC CACTCACTATGTTGGTGYCATTTTT GCCASCACCTCWACTCCNACAC YACAYTWACCACATTNGTSGM	69 (62-83)	388/500 (78%) [No target overlap with other DBL β primers]	
DBLe2 (DBLe2)	AAAWTTAATWGTTGGRAGCAC AATTTRATWGTTAAATGCAYACA	GACATAATTGTTGYACTCTAGGAGRMA	86 (85-89)	335/416 (80%)	
DBLe6 (DBLe6)	GTTGCATAYAATGAAGGTTATTCCT AAAACTRRACTTATGAATTSTGCCTACA ATTTCTCAATATGYCTAYACTSAAGGA	ATCHGTWCCTTAACTATATCTCCATA ATCTYTACCTTTACTATATCAGCAAT	127 (117-135)	335/442 (76%)	
DBLe11 (DBLe11)	AAAGHATTACAAAAAGAYGCATAT CATTACAATATGTGCATAATAAAG AAATACAGGAATCAGCATAAACGAAG	TTCCTTTAATTAATYASCATAATCWGA TCAGCATAACTYCTTTCATATTTCA	177 (151-178)	287/315 (91%)	
DBLe13 (DBLe13)	CTGTTGCTGCAAATSAAGGATAAT CTGCTGYTGCAGATGATGCATAAT	ATAATCRTAAAACRTTATTCATGCT	107 (107-107)	185/196 (85%)	
DBLe14 (DBLe14)	TTTAAYCAAGGAATWCTTTAGGAA	ATATCTSCATARTCAGAAAATAT	95 (95-101)	117/137 (85%)	
DBLe_all (DBLe2/6/11/13/14)	Comment: A summarized transcript level for all DBLe primers. There is no overlap between the primer sets summarized.				
DBLz2a (DBLz2)	CCTCAACGTTTRAGATGGATGAAG	ATTTTGCAAACATAYTCTCCCCATT	50 (50-50)	64/336 (19%)	

Primer name (Target domain type)	Forward primers	Reverse primers	Amplicon size	Coverage	Specificity	
	Mixed to a final total primer concentration of 20 μ M	Mixed to a final total primer concentration of 20 μ M	Median (Min - Max) bp	Number of sequences amplified with intended domain class / number of sequences with intended domain class (%)	Number of sequences amplified with intended domain class / number of domain sequences amplified (%)	
DBLz2b (DBL ζ 2)	AGTGACCCTCCGTGGATGATTA	TGCAATAATTTCACTCCATTCTT	73 (73-73)	114/336 (34%)	114/114 (100%)	
DBLz2c (DBL ζ 2)	ATGTRCCTCAAATCTTAGATGGATWA	TTCTTGCAATTACAAAAATGTC	62 (62-62)	104/336 (31%)	104/104 (100%)	
DBLz2 (DBL ζ 2)	Comment: A summarized transcript level for DBL ζ 2 domains (DBLz2a+DBLz2b+DBLz2c). There is no overlap between the primer sets summarized.			282/336 (84%)	282/371 (76%)	
DBLz3 (DBL ζ 3)	AACCTCCTTATGTTGATTACATTCCACA ATCCTCCTTATGATGATTATATWCWCA	TTCTGACCATTCAAGTCATCCATCT	59 (59-59)	90/264 (34%)	90/90 (100%)	
DBLz5 (DBL ζ 5)	GATTATGATTATATYCCCTAACCTT	TTCRCYCCATTCACTTAKCCAKCG	51 (51-51)	233/248 (94%)	233/233 (100%)	
DBLz4 (DBL ζ 4)	AACCTCCTGATTATGATTATATACT	CAATAATATTCACTCCATTCTTGC	67 (67-67)	281/302 (93%)	281/390 (72%) [55% of targets also targeted by DBLz6]	
DBLz6 (DBL ζ 6)	CCTGATTATGATTATATWCYCAACCTT	TTCACTCCATTCTTGCATSMACG	54 (54-54)	324/400 (81%)	324/444 (73%)	
DBLz4/6 (DBL ζ 4/6)	Comment: Due to the considerable overlap between DBLz4 and DBLz6 primer sets, the transcript level for these domains were analysed using only the data from the primer reporting highest transcript level, i.e. either DBLz4 or the DBLz6 primer.					
DBLz_all (DBL ζ)	Comment: The summarized transcript level for all DBL ζ domains calculated as sum of DBLz2+z3+z4/6. There is no overlap between the primer sets summarized.					
var3 (DBLe8 aka DC3 aka DBL ζ -DBLe8)	AAGAGGGATCTACTTAATGCTGTTTAG	AACTGAACCTCATGCCCTATATGC	99 (99-99)	164/164 (100%)	164/164 (100%)	


† "DBLe8" from Lavstsen et al. PNAS, 2012

Primer name (Target domain type)	Forward primers	Reverse primers	Amplicon size	Coverage	Specificity
	Mixed to a final total primer concentration of 20 μ M	Mixed to a final total primer concentration of 20 μ M	Median (Min - Max) bp	Number of sequences amplified with intended domain class / number of sequences with intended domain class (%)	Number of sequences amplified with intended domain class / number of domain sequences amplified (%) Specificity graphic
var2csa (DBLpam3 aka. DBL3x)	AATGGGACAAACAAAAACAAAATATG	GCTGATATACATTAGGATAATTTC	94 (94-94)	265/265 (100%)	265/265 (100%) 
↑ "T12/T13" from Sander et al. PLoS One, 2009					
Supplementary Figure 1B - In silico comparison of new DBLa targeting primers to old versions published by Lavstsen et al. PNAS, 2012					
Primer name (Target)	Forward primers	Reverse primers	Amplicon size	Coverage	Specificity
	Mixed to a final total primer concentration of 20 μ M	Mixed to a final total primer concentration of 20 μ M	Median (Min - Max) bp	Number of sequences amplified with intended domain class / number of sequences with intended domain class (%)	Number of sequences amplified with intended domain class / number of domain sequences amplified (%) Distribution of the CIDR1 subclasses linked to targeted DBLa sequences
DBLa1.5/6a Lavstsen et al PNAS, 2012	GATTAYGTCCCTCAATTTTAMGWTGGT	GATTTGTTTATTACAATCGTAACCCTC	157 (157-160)	26%	100% 
DBLa1.5/6b Lavstsen et al PNAS, 2012	ATTGTAGTMRKGAGGGTTACGATTGTA	CWTYTKCACAAVKGGACAWTCTARATC	90 (90-90)	48%	97% 
DBLa1.5/6/8 (DBLa1.5/6/8) Present study	GATTAYGTBCCTCAATTTTAMGWTGGT	GATTGTTTWTTACAATCGTAACCCCTC GATCTGTCGTTACAATCGTAACCCCTC TTTAGTACAATCATAACCATACCCA ACAATCCTCACCATACCAACTACAAT CGTGATATATCTGTTKAGTACAATC	157 (144-173)	73%	90% 
DBLa1 not var3 Lavstsen et al PNAS, 2012	TTGGGRAATBTGTTAGTTAYRGCAA	CTGCAAAACTKCGWGAAG	109 (109-121)	72%	89% 
DBLa1all (DBLa1.1-8) Present study	TTGGGAAATGTRTRGTTACAGCAAA TTGGGAAATGTTAGTTATGGCAAA TTGGGAAATTGTTAGTTATGGCAAG TTGGGAAACCTATTAGTTATGGCAA TTAGGAAATATTGGTAGCAGCAA TTAGGAAATATCTGGTCACAGCAA	CCTATATCNGCAAACTCKWG	116 (116-128)	92%	100% 
DBLa2/a1.1/2/4/7 Lavstsen et al PNAS, 2012	TCCTACCAATTAGATTACGTCCCTCA	CGTACAATCATATCCATTAAGACTAC	160 (160-169)	33%	97% 
DBLa2/1.1/2/4/7 (DBLa2/1.1/2/4/7) Present study	GATTAYGTBCCTCAATTTTAMGWTGGT	TACAAATCATCCATTAGACTACAA TCACAATCGCATCCATTATGACTACAA	145 (145-157)	82%	82% 


Supplementary figure 1 A) In silico characterization of *var* gene primers used in the present study. **B)** In silico comparison of new DBL α targeting primers to old versions published by Lavstsen et al. PNAS, 2012. The primer sets DBL α 1all, DBL α 1.5/6/8 and DBL α 2/1.1/2/4/7 target loci encoding DBL α domains, and replaced previously published primer sets designed for identical *var* subsets. A comparison of predicted coverage and specificity of new and old primer sets is given, as is a distribution of the C-terminally linked CIDR types of the targeted genes. The linkages to CIDR types help assess data reported by DBL α primers in relation to known binding phenotypes mediated by the CIDR domains.



Supplementary Figure 2. Overview of PfEMP1 domain classes, the estimated proportion of *var* genes encoding these, and coverage of the primer set. X indicate domain classes indirectly accounted for by primers targeting linked domain classes.



Supplementary Figure 3: Transcript levels by primer sets reporting statistically significant different transcript levels between hospitalized patients with uncomplicated and severe malaria. Median (25 and 75 percentiles, upper and lower adjacent values and outliers) var transcript levels (Tu) reported in children hospitalized with uncomplicated (N=42) or severe malaria (N=123). P values are for comparison of levels in the two groups of patients (uncomplicated and severe malaria patients) (Wilcoxon rank sum test).



Supplementary Figure 4: Median (25 and 75 percentiles, upper and lower adjacent values and outliers) var transcript levels (Tu) reported in children with severe malarial anaemia (N=44) or cerebral malaria (N=29) with the primer set targeting DBL1/3-1.

Supplementary Table 1. Percentage of individuals of each patient group with *var* transcript levels higher than 16 Tu

Primer(s)	UM (%) (95% C.I.)	SM (%) (95% C.I.)	UM vs. SM P	SA (%) (95% C.I.)	CM (%) (95% C.I.)	SA vs. CM P
CIDRa1.all > 16 Tu	86	86		84	83	
CIDRa1.DC8 > 16 Tu	43 (28-58)	64 (56-73)	0.015	55	62	
CIDRa1.A > 16 Tu	67	61		52	59	
CIDRd > 16 Tu	14	12		13	24	
DBLb1/3-1 > 16 Tu	10	8		2 (0-12)	24 (12-42)	0.01
DBLz_all > 16 Tu	40	58		55	72	

P values calculated using Fishers Exact test. 95% confidence intervals only shown for P values < 0.05 shown.